Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Emcure Pharmaceuticals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: EMCURE | BSE: 544210

₹1,853.80

up-down-arrow ₹-15.60 (-0.83%)

As on 31-Aug-2026 12:44IST

Market cap

info icon

₹35,050 Cr

Revenue (TTM)

info icon

₹9,683 Cr

P/E Ratio

info icon

34.7

P/B Ratio

info icon

6.7

Div. Yield

info icon

0.2 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 4.48 22.85 18.36 15.42 8.73
EBIT 13.32 33.30 30.43 13.05 7.93
Net Profit 24.54 40.36 36.84 18.77 17.59
EPS 20.72 41.92 35.74 18.34 17.59
Book Value -- -- 11.30 23.74 15.81
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 10.2215.1815.6814.4613.74
Net Margin info 8.219.6010.4710.088.88
Return on equity info 14.4323.4321.3020.0919.19
Return on Capital info 16.7923.23--25.2522.49
Return on Assets info 7.199.4311.4210.708.94
Debt to Equity (x) info ----0.050.240.17

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
25.25
22.49
19.87
21.97
Peer Median
--
15.48
16.46
15.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

21.30

Higher than Peers by 11.35

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
21.30
20.09
19.19
19.45
25.21
Peer Median
9.94
12.68
13.87
14.72
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

11.42

Higher than Peers by 4.16

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
11.42
10.70
8.94
7.39
8.97
Peer Median
7.26
7.69
8.04
7.19
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

15.68

Higher than Peers by 6.14

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
15.68
14.46
13.74
13.78
15.39
Peer Median
9.55
15.68
10.05
10.28
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

10.47

Higher than Peers by 1.84

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
10.47
10.08
8.88
7.86
9.31
Peer Median
8.64
11.16
9.11
6.78
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
14.44
13.61
12.38
13.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

18.36

Higher than Peers by 12.12

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
18.36
16.56
18.59
11.23
2.23
Peer Median
6.24
15.05
7.17
10.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

30.43

Higher than Peers by 30.49

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
30.43
22.68
18.25
-0.41
-15.11
Peer Median
-0.06
19.88
12.05
6.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

36.84

Higher than Peers by 29.26

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
36.84
33.05
34.10
-6.10
-20.03
Peer Median
7.58
19.11
22.15
27.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

35.74

Higher than Peers by 33.56

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
35.74
35.59
30.75
-6.52
-19.66
Peer Median
2.18
23.11
8.80
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
11.36
50.94
18.16
26.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.05

Higher than Peers by 0.03

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
0.05
0.24
0.17
0.71
0.88
Peer Median
0.02
0.12
0.03
0.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
0.16
0.11
0.32
0.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.43

Lower than Peers by 1.01

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
1.43
1.43
1.71
1.33
1.27
Peer Median
2.45
2.48
2.20
1.93
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.82

Lower than Peers by 0.89

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
0.82
0.82
0.98
0.85
0.81
Peer Median
1.72
1.82
1.72
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

10.36

Higher than Peers by 0.65

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
10.36
9.96
6.53
4.07
4.50
Peer Median
9.71
13.67
12.28
12.45
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

26.46

Lower than Peers by 0.45

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
26.46
27.84
25.36
27.92
27.54
Peer Median
26.91
30.65
26.23
23.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

1.09

Higher than Peers by 0.41

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
1.09
1.07
1.01
0.95
0.97
Peer Median
0.67
0.70
0.74
0.88
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
88.68
87.83
94.32
88.49
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
84.11
78.64
78.21
84.77
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
176.65
174.97
193.72
194.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
--
-3.86
-8.50
-21.19
-21.59
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

34.66

Lower than Peers by 20.41

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
34.66
32.73
29.84
--
--
Peer Median
55.07
55.07
39.17
40.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

6.70

Higher than Peers by 2.22

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
6.70
6.13
4.58
--
--
Peer Median
4.48
4.76
3.61
3.87
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.20

Higher than Peers by 0.05

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
0.20
0.23
0.28
--
--
Peer Median
0.15
0.15
0.19
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

18.13

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
18.13
16.68
13.55
1.57
1.55
Peer Median
--
39.78
28.79
25.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

35,050

Higher than Peers by 29,230

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Emcure Pharmaceuticals
35,050
30,258
20,327
--
--
Peer Median
5,820
5,820
3,944
2,959
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...